TBA-7371 | CAS#1494675-86-3 | DprE1 inhibitor

MedKoo Cat#: 464590 | Name: TBA-7371

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TBA-7371, also known as AZ 7371, is a non-covalent inhibitor of decaprenylphosphoryl-β-D-ribose 2’-epimerase (DprE1; IC50 = 10 nM), an enzyme involved in mycobacterial cell wall biogenesis.

Chemical Structure

TBA-7371

CAS#1494675-86-3

Theoretical Analysis

MedKoo Cat#: 464590

Name: TBA-7371

CAS#: 1494675-86-3

Chemical Formula: C18H21N5O3

Exact Mass: 355.1644

Molecular Weight: 355.40

Elemental Analysis: C, 60.83; H, 5.96; N, 19.71; O, 13.51

Price and Availability

Size	Price	Availability
1mg	USD 190.00	2 Weeks
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TBA-7371; TBA7371; TBA 7371; AZ 7371; AZ-7371; AZ7371;

IUPAC/Chemical Name

N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide

InChi Key

VDRYGTNDKXIPSK-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)

SMILES Code

COC1=C(C)C(CN2C(C=C(C)C=N3)=C3C(C(NCCO)=O)=C2)=NC=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 355.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: El Haddoumi G, Mansouri M, Kourou J, Belyamani L, Ibrahimi A, Kandoussi I. Targeting decaprenylphosphoryl-β-D-ribose 2'-epimerase for Innovative Drug Development Against Mycobacterium Tuberculosis Drug-Resistant Strains. Bioinform Biol Insights. 2024 May 28;18:11779322241257039. doi: 10.1177/11779322241257039. PMID: 38812740; PMCID: PMC11135120. 2: Li S-Y, Tyagi S, Soni H, Betoudji F, Converse PJ, Mdluli K, Upton AM, Fotouhi N, Barros-Aguirre D, Ballell L, Jimenez-Navarro E, Nuermberger EL. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0156223. doi: 10.1128/aac.01562-23. Epub 2024 Feb 20. PMID: 38376228; PMCID: PMC10989019. 3: Yang L, Hu X, Lu Y, Xu R, Xu Y, Ma W, Alam MS, Zhang T, Chai X, Lei Y, Ye Q, Dong X, Kang Y, Che J, Hou T, Li D. Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis. J Med Chem. 2024 Feb 8;67(3):1914-1931. doi: 10.1021/acs.jmedchem.3c01703. Epub 2024 Jan 17. PMID: 38232131. 4: Almeida DV, Converse PJ, Nuermberger EL. Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0005223. doi: 10.1128/aac.00052-23. Epub 2023 Feb 14. PMID: 36786606; PMCID: PMC10019223. 5: Finger V, Kufa M, Soukup O, Castagnolo D, Roh J, Korabecny J. Pyrimidine derivatives with antitubercular activity. Eur J Med Chem. 2023 Jan 15;246:114946. doi: 10.1016/j.ejmech.2022.114946. Epub 2022 Nov 22. PMID: 36459759. 6: Robertson GT, Ramey ME, Massoudi LM, Carter CL, Zimmerman M, Kaya F, Graham BG, Gruppo V, Hastings C, Woolhiser LK, Scott DWL, Asay BC, Eshun-Wilson F, Maidj E, Podell BK, Vásquez JJ, Lyons MA, Dartois V, Lenaerts AJ. Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0058321. doi: 10.1128/AAC.00583-21. Epub 2021 Aug 9. PMID: 34370580; PMCID: PMC8522729. 7: Nandi S, Saxena AK. Exploring Targets of Cell Wall Protein Synthesis and Overexpression Mediated Drug Resistance for the Discovery of Potential M. tb Inhibitors. Curr Top Med Chem. 2021;21(21):1922-1942. doi: 10.2174/1568026621666210727165742. PMID: 34315374.